Back to Search Start Over

Oral Arsenic-Containing Qinghuang Powder: A Potential Drug for Myelodysplastic Syndromes.

Authors :
Ming J
Liu WY
Xiao HY
Xu YG
Ma R
Hu XM
Source :
Chinese journal of integrative medicine [Chin J Integr Med] 2022 Aug; Vol. 28 (8), pp. 762-768. Date of Electronic Publication: 2020 Mar 07.
Publication Year :
2022

Abstract

Qinghuang Powder (QHP), an oral arsenic, has become an effective drug in the treatment of myelodysplastic syndromes (MDS) in Xiyuan Hospital, China Academy of Chinese Medical Sciences for many years, and the action mechanism of the compound or active ingredient As <subscript>2</subscript> S <subscript>2</subscript> of QHP has been elucidated. Considering the relatively safety, chemotherapy-free and convenient oral profile, QHP is widely used in the clinical treatment for MDS patients, especially for elderly patients. In this review, the authors document the efficacy and safety of oral arsenic-containing compound QHP in the treatment of MDS, with a special focus on the association of efficacy of QHP with the cytogenetics, prognostic risk, DNA methylation, gene mutation, blood arsenic concentration, mechanism of action of As <subscript>2</subscript> S <subscript>2</subscript> and the countermeasures against adverse reactions of gastrointestinal tract.<br /> (© 2020. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.)

Details

Language :
English
ISSN :
1993-0402
Volume :
28
Issue :
8
Database :
MEDLINE
Journal :
Chinese journal of integrative medicine
Publication Type :
Academic Journal
Accession number :
32146594
Full Text :
https://doi.org/10.1007/s11655-020-3254-9